All In Biotech

Drug Trial Radar · NCT04906434

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Feb 26, 2020

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase 1 study with an escalation part and an expansion part.

Conditions

  • Advanced Liver Cancer

Interventions

  • ABSK-011Drug

    During the escalation part, the administration of oral ABSK-011 will be guided by "3+3"design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data. A separate food effect cohort may be conducted. In expansion part, patients will be treated at the selected RDE dose level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTTime frame: From the starting dosing of study drug to the end of Cycle 1 (each cycle is 28 days) in escalation Part
  2. Incidence and severity of AEs, AESIs and SAEsTime frame: 30 days after last administration, an average of one half year
  3. dose reduction or discontinuationTime frame: through study completion, an average of one half year
  4. physical examinations changes from baselineTime frame: through study completion, an average of one half year
  5. ECOG performance statusTime frame: through study completion, an average of one half year
  6. electrocardiograms (ECGs)Time frame: through study completion, an average of one half year
  7. echocardiograms changes from baselineTime frame: through study completion, an average of one half year
  8. vital signs changes from baselineTime frame: through study completion, an average of one half year
  9. vital signs changes from baselineTime frame: through study completion, an average of one half year
  10. vital signs changes from baselineTime frame: through study completion, an average of one half year

Locations

32 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Completed

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army

    Beijing, Beijing Municipality, China · Withdrawn

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China · Completed

  • Sun Yat Sen Memorial Hospital

    Guangzhou, Guangdong, China · Completed

  • Guangxi Zhuang Autonomous Region People's Hospital

    Nanning, Guangxi, China · Completed

  • Weifang People's Hospital

    Weifang, Hebei, China · Completed

  • Harbin Medical University Cancer Hospital

    Haerbin, Heilongjiang, China · Recruiting

  • First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Completed

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Completed

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Completed

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Completed

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China · Withdrawn

  • Suzhou University Affiliated Second Hospital

    Suzhou, Jiangsu, China · Completed

  • Tonghua Central Hospital

    Tonghua, Jilin, China · Completed

  • Shengjing Hospital of China medical university

    Shenyang, Liaoning, China · Completed

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China · Completed

  • Jinan Central Hospital

    Jinan, Shandong, China · Completed

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Completed

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xian, Shanxi, China · Withdrawn

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Recruiting

  • Ningbo Huamei Hospital, University of Chinese Academy of Sciences

    Ningbo, Zhejiang, China · Withdrawn

  • National Cheng Kung University Hospitals

    Tainan, Taiwan · Completed

  • Nation Taiwan University Hospital

    Taipei, Taiwan · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.